BioSpace News Archive

U.K. medical chart study showed an association between patients treated with terlipressin and an improvement in kidney function in 73 percent of hospitalized adult patients with HRS-1

Lannett Company, Inc. said that representatives from the company spoke with and received guidance from the U.S. Food and Drug Administration on the clinical advancement program of its biosimilar insulin glargine partnered product candidate.

Lupin Pharmaceuticals Inc. is voluntarily recalling Metformin Hydrochloride Extended-Release Tablets USP, 500mg, lot G901203 to the consumer level.

Metagenomics is defined as the extensive study of various types of genetic material recovered directly from environmental samples, which is further used for many purposes such as identification of a microbial species, classification of microorganisms, and understanding their importance on the planet dating back to their origin.

Microtomes are instruments that are used for making extremely thin sections of a specimen for applications in pathology or histology.

The global animal blood plasma products and derivatives market is has a fragmented vendor landscape due to the presence of several players, Transparency Market Research observes.

Transparency Market Research has published a new report titled, “Pediatric Neuroblastoma Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026.” According to the report, the global pediatric neuroblastoma treatment market is projected to reach US$ 1.3 Bn by 2026 at a considerable CAGR from 2018 to 2026.

Transparency Market Research has published a new report titled, “Head and Neck Cancer Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026”.

The global chronic kidney disease drugs is predicted in a report by Transparency Market Research finds intense competition and high fragmentation owing to presence of strong players in the market.

Lyndra Therapeutics achieved significant milestones in the first half of 2020 despite COVID-19 headwinds, naming Örn Almarsson as Chief Technology Officer, completing enrollment and dosing of its Phase I clinical trial for an ultra-long-acting oral risperidone therapy to treat schizophrenia, ramping up manufacturing capabilities and growing its employee base by 28%.